Mr. Vincent Lum reports

PANGENOMIC HEALTH SUBSIDIARY LAUNCHES VITAMIN D HEALTH ASSESSMENTS AND ANNOUNCES CORPORATE APPOINTMENTS

Pangenomic Health Inc.'s subsidiary, MUJN Diagnostics Inc., has commenced a vitamin D health assessment service and has also launched a corporate website at mujn.ai.

"We are very excited to introduce the MUJN biomarker assessment platform at Vancouver-based Empower Health Wellness Centre. Our first service provides Empower Health practitioners with rapid in-clinic access to patient Vitamin D assessments," said Vincent Lum, CEO of MUJN Diagnostics and Co-Founder ofPangenomic Health. "Vitamin D deficiency is a global public health problem affecting over one billion people, regardless of age, ethnicity or location. Almost 20% of Canadians have deficient levels of Vitamin D due to cloud cover, smog, sunscreens, or staying indoors.1"

Current clinical research on Vitamin D has found that:

• Vitamin D helps to absorb dietary calcium and phosphorus from the intestine for use in the body for bone strength and a large variety of your body functions.
• Vitamin D suppresses the release of parathyroid hormone, a hormone that causes bone breakdown leading to osteoporosis.
• Vitamin D supports overall brain and other organ system health by strengthening the immune system. 2

Corporate Appointments

The Company is pleased to announce that its Chief Technology Officer, Colin Quon, has been appointed CTO of MUJN Diagnostics and will cease his role as CTO ofPangenomic Health effective immediately. Mr. Quon's focus as CTO will be on the development of the MUJN Diagnostic Support System, previously announced by the Company on March 22, 2023.

The Company is also pleased to confirm that Maryam Marissen was appointed a Director of the Company at its annual general meeting of shareholders held on April 26, 2023. Ms. Marissen has been CEO ofPangenomic Health since September 2022. Prior to joining Pangenomic Health Ms. Marissen served as Chief Executive Officer at Doseology Sciences from 2021-2022,

Maryam Marissen owns 1,000,000 stock options in the Company as at the date of th

is announcement.
  
   Other Current Directorships      Former Directorships and/or 
                                    partnerships (within the last five years)
PanGenomic Technologies Corp.  
(a subsidiary of Pangenomic Health) Vancouver TRU Cosmetics Ltd.                                         
TruMIND Wellness Inc.               Doseology Sciences Inc.                                              
Eternal Skin Care (USA) Inc.                                                                                                            


  

Except as set out above, there is no further information regarding Maryam Marissen that is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.

The Directors ofPangenomic Health take responsibility for this announcement.

About MUJN Diagnostics

MUJN Diagnostics Inc. is a wholly-owned subsidiary ofPangenomic Health Inc. and is focused on developing a decision support system for alternative healthcare providers. MUJN's Decision Support System will include biomarker diagnostics, symptom and treatment tracking, and personalized health analytics, with the goal of empowering healthcare providers and their patients towards better outcomes.

AboutPangenomic Health

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company,Pangenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

We seek Safe Harbor.